NCT01299298 - A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Doses of Mipomersen in Japanese Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

April 30, 2011

Study Completion Date

April 30, 2011

Conditions

Healthy Volunteer

Interventions

DRUG

mipomersen

50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug

DRUG

placebo

50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug

Trial Locations (1)

FOCUS Clinical Drug Development GmbH, Stresemannallee 6, Neuss